ContractWarrant Agreement • March 13th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.
NET COMMERCIAL LEASECommercial Lease • March 13th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Lease dated January 7, 2017, for reference purposes only, is by and between 546 ECCLES AVENUE, A CALIFORNIA LIMITED PARTNERSHIP (“Lessor”) and Audentes Therapeutics, Inc., a Delaware corporation (“Lessee”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 13th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of March 7, 2017 and is entered into by and between AUDENTES THERAPEUTICS, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as “Lender”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lender (in such capacity, the “Agent”).
FIRST AMENDMENT TO OFFICE LEASEOffice Lease • March 13th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
*The Original Premises Base Rent for the first three (3) months of the Initial Lease Term following the Commencement Date (February 18, 2016 through May l7, 2016) shall be abated but shall become immediately due and payable if at any time during the Initial Lease Term, there is an uncured Event of Default by Tenant as described below.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTPlan • March 13th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT (“First Amendment”) is entered into as of December 21, 2016 (the “First Amendment Effective Date”) by and between Audentes Therapeutics Inc., having its principal offices at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Licensor”), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Institution”). Licensor and Institution are sometimes hereinafter referred to collectively as the “Parties” and individually as a “Party.”
FIRST AMENDMENT TO LEASE AGREEMENT Property Address: 550-3 Eccles Avenue South San Francisco, CaliforniaLease Agreement • March 13th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment to Lease Agreement (this “Amendment”), dated for reference purposes January 13, 2017, is incorporated into and made a part of that certain Net Commercial Lease agreement (“Lease Agreement”) dated January 7, 2017 between 546 Eccles Avenue, a California limited partnership (“Lessor”) and Audentes Therapeutics, Inc., a Delaware corporation (“Lessee”) for that certain real estate known and described as 550-3 Eccles Avenue, in the City of South San Francisco, County of San Mateo, State of California (the “Property”).
